Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Lung cancer; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 29 Sep 2018 Planned End Date changed from 31 Mar 2020 to 31 Dec 2018.
- 29 Sep 2018 Status changed from suspended to discontinued.
- 11 May 2018 Planned End Date changed from 1 Mar 2016 to 31 Mar 2020.